

1 KAMALA D. HARRIS
Attorney General of California
2 JOSHUA A. ROOM
Supervising Deputy Attorney General
3 BRETT A. KINGSBURY
Deputy Attorney General
4 State Bar No. 243744
455 Golden Gate Avenue, Suite 11000
5 San Francisco, CA 94102-7004
Telephone: (415) 703-1192
6 Facsimile: (415) 703-5480
Attorneys for Complainant

7
8 **BEFORE THE**
BOARD OF PHARMACY
9 **DEPARTMENT OF CONSUMER AFFAIRS**
STATE OF CALIFORNIA

10 In the Matter of the Accusation Against:

Case No. 4667

11 **HS PHARMACY D.B.A. HIGH STREET**
12 **PHARMACY**
13 **4248 Macarthur Blvd.**
Oakland, CA 94619
14 **Original Permit Number PHY 48720**

ACCUSATION

15 **GAREEN AVAKIAN**
16 **1 Lakeside Dr., #506**
Oakland, CA 94612-
Original Pharmacist License No. RPH 44906

17 and,

18 **KENNETH PAUL MARINAI**
19 **1180 Monticello Rd.**
Lafayette, CA 94549
20 **Original Pharmacist License No. RPH 28204**

21 Respondents.

22
23 Complainant alleges:

24 **PARTIES**

25 1. Virginia Herold (Complainant) brings this Accusation solely in her official capacity
26 as the Executive Officer of the Board of Pharmacy, Department of Consumer Affairs.

27 2. On or about October 9, 2007, the Board of Pharmacy (Board) issued Pharmacy
28 License Number PHY 48720 to HS Pharmacy Inc. d.b.a. High Street Pharmacy, at 4248

1 Macarthur Blvd., Oakland, CA 94619 (Respondent High Street). Respondent High Street's
2 Pharmacy License was in full force and effect at all times relevant to the charges brought herein
3 and will expire on October 1, 2016, unless renewed.

4 3. On or about October 7, 1991, the Board issued Pharmacist License Number RPH
5 44906 to Gareen Avakian (Respondent Avakian). The Pharmacist License has been in full force
6 and effect at all times relevant to the charges brought herein and will expire on August 31, 2017,
7 unless renewed. Respondent Avakian has been the Pharmacist-in-Charge (PIC) of Respondent
8 High Street since May 1, 2012; has been the Vice President of Respondent High Street since
9 October 9, 2007; and has been the Chief Executive Officer, President, Secretary, Treasurer, and
10 Chief Financial Officer of Respondent High Street since April 12, 2012. In addition, Respondent
11 Avakian became a partial owner of Respondent High Street in 2007, and became the sole owner
12 of Respondent High Street in April 2012.

13 4. On or about April 24, 1973, the Board issued Pharmacist License Number RPH
14 28204 to Kenneth Paul Marinai (Respondent Marinai). The Pharmacist License was in full force
15 and effect at all times relevant to the charges brought herein and will expire on January 31, 2017,
16 unless renewed.

17 JURISDICTION

18 5. This Accusation is brought before the Board, Department of Consumer Affairs, under
19 the authority of the following laws. All section references are to the Business and Professions
20 Code (Code) unless otherwise indicated.

21 6. Section 4011 of the Code provides that the Board shall administer and enforce both
22 the Pharmacy Law [Bus. & Prof. Code, § 4000 et seq.] and the Uniform Controlled Substances
23 Act [Health & Safety Code, § 11000 et seq.].

24 7. Section 4300(a) of the Code provides that every license issued by the Board may be
25 suspended or revoked.

26 ///

27 ///

28 ///

1 11. Section 4081 of the Code states:

2 "(a) All records of manufacture and of sale, acquisition, or disposition of dangerous drugs
3 or dangerous devices shall be at all times during business hours open to inspection by authorized
4 officers of the law, and shall be preserved for at least three years from the date of making. A
5 current inventory shall be kept by every manufacturer, wholesaler, pharmacy, veterinary
6 food-animal drug retailer, physician, dentist, podiatrist, veterinarian, laboratory, clinic, hospital,
7 institution, or establishment holding a currently valid and unrevoked certificate, license, permit,
8 registration, or exemption under Division 2 (commencing with Section 1200) of the Health and
9 Safety Code or under Part 4 (commencing with Section 16000) of Division 9 of the Welfare and
10 Institutions Code who maintains a stock of dangerous drugs or dangerous devices.

11 "(b) The owner, officer, and partner of any pharmacy, wholesaler, or veterinary food-animal
12 drug retailer shall be jointly responsible, with the pharmacist-in-charge or representative-in-
13 charge, for maintaining the records and inventory described in this section.

14 "(c) The pharmacist-in-charge or representative-in-charge shall not be criminally
15 responsible for acts of the owner, officer, partner, or employee that violate this section and of
16 which the pharmacist-in-charge or representative-in-charge had no knowledge, or in which he or
17 she did not knowingly participate."

18 12. Section 4113(c) of the Code states:

19 "The pharmacist-in-charge shall be responsible for a pharmacy's compliance with all state
20 and federal laws and regulations pertaining to the practice of pharmacy."

21 13. Section 4156 of the Code provides:

22 "A pharmacy corporation shall not do, or fail to do, any act where doing or failing to do the
23 act would constitute unprofessional conduct under any statute or regulation. In the conduct of its
24 practice, a pharmacy corporation shall observe and be bound by the laws and regulations that
25 apply to a person licensed under this chapter."

26 ///

27 ///

28 ///

1 14. Section 4301 of the Code states:

2 "The board shall take action against any holder of a license who is guilty of unprofessional
3 conduct or whose license has been issued by mistake. Unprofessional conduct shall include, but is
4 not limited to, any of the following:

5 ". . . .

6 "(o) Violating or attempting to violate, directly or indirectly, or assisting in or abetting the
7 violation of or conspiring to violate any provision or term of this chapter or of the applicable
8 federal and state laws and regulations governing pharmacy, including regulations established by
9 the board or by any other state or federal regulatory agency.

10 ". . . ."

11 15. Section 4302 of the Code provides:

12 "The board may deny, suspend, or revoke any license of a corporation where conditions
13 exist in relation to any person holding 10 percent or more of the corporate stock of the
14 corporation, or where conditions exist in relation to any officer or director of the corporation that
15 would constitute grounds for disciplinary action against a licensee."

16 16. Code section 4306.5 provides:

17 "Unprofessional conduct for a pharmacist may include any of the following:

18 ". . . .

19 "(b) Acts or omissions that involve, in whole or in part, the failure to exercise or implement
20 his or her best professional judgment or corresponding responsibility with regard to the
21 dispensing or furnishing of controlled substances, dangerous drugs, or dangerous devices, or with
22 regard to the provision of services.

23 ". . . ."

24 17. Section 4332 of the Code provides:

25 "Any person who fails, neglects, or refuses to maintain the records required by section 4081
26 or who, when called upon by an authorized officer or a member of the board, fails, neglects, or
27 refuses to produce or provide the records within a reasonable time . . . is guilty of a
28 misdemeanor."

1 18. California Code of Regulations, title 16, section 1714(c) provides:

2 "The pharmacy and fixtures and equipment shall be maintained in a clean and orderly
3 condition. The pharmacy shall be dry, well-ventilated, free from rodents and insects, and properly
4 lighted. The pharmacy shall be equipped with a sink with hot and cold running water for
5 pharmaceutical purposes."

6 19. California Code of Regulations, title 16, section 1707.2 provides:

7 "(a) A pharmacist shall provide oral consultation to his or her patient or the patient's agent
8 in all care settings:

9 "(1) upon request; or

10 "(2) whenever the pharmacist deems it warranted in the exercise of his or her professional
11 judgment.

12 "(b)(1) In addition to the obligation to consult set forth in subsection (a), a pharmacist shall
13 provide oral consultation to his or her patient or the patient's agent in any care setting in which the
14 patient or agent is present:

15 "(A) whenever the prescription drug has not previously been dispensed to a patient; or

16 "(B) whenever a prescription drug not previously dispensed to a patient in the same dosage
17 form, strength or with the same written directions, is dispensed by the pharmacy.

18 "(2) When the patient or agent is not present (including but not limited to a prescription
19 drug that was shipped by mail) a pharmacy shall ensure that the patient receives written notice:

20 "(A) of his or her right to request consultation; and

21 "(B) a telephone number from which the patient may obtain oral consultation from a
22 pharmacist who has ready access to the patient's record.

23 ". . . .

24 "(e) Notwithstanding the requirements set forth in subsection (a) and (b), a pharmacist is not
25 required to provide oral consultation when a patient or the patient's agent refuses such
26 consultation."

27 ///

28 ///

1 20. California Code of Regulations, title 16, section 1715(a) provides:

2 "The pharmacist-in-charge of each pharmacy as defined under section 4029 or section 4037
3 of the Business and Professions Code shall complete a self-assessment of the pharmacy's
4 compliance with federal and state pharmacy law. The assessment shall be performed before July 1
5 of every odd-numbered year. The primary purpose of the self-assessment is to promote
6 compliance through self-examination and education."

7 21. California Code of Regulations, title 16, section 1716 provides, in pertinent part, that
8 pharmacists shall not deviate from the requirements of a prescription except upon the prior
9 consent of the prescriber or to select the drug product in accordance with Section 4073 of the
10 Code (pertaining to substitution of generic for brand name).

11 22. California Code of Regulations, title 16, section 1718 states:

12 "'Current Inventory' as used in Sections 4081 and 4332 of the Business and Professions
13 Code shall be considered to include complete accountability for all dangerous drugs handled by
14 every licensee enumerated in Sections 4081 and 4332.

15 "The controlled substances inventories required by Title 21, CFR, Section 1304 shall be
16 available for inspection upon request for at least 3 years after the date of the inventory."

17 23. California Code of Regulations, title 16, section 1735.2 states, in pertinent part:

18 "(a)

19 ". . . .

20 "(d) A drug product shall not be compounded until the pharmacy has first prepared a written
21 master formula record that includes at least the following elements:

22 "(1) Active ingredients to be used.

23 "(2) Equipment to be used.

24 "(3) Expiration dating requirements.

25 "(4) Inactive ingredients to be used.

26 "(5) Process and/or procedure used to prepare the drug.

27 "(6) Quality reviews required at each step in preparation of the drug.

28 "(7) Post-compounding process or procedures required, if any.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

". . . .

"(h) Every compounded drug product shall be given an expiration date representing the date beyond which, in the professional judgment of the pharmacist performing or supervising the compounding, it should not be used. This "beyond use date" of the compounded drug product shall not exceed 180 days from preparation or the shortest expiration date of any component in the compounded drug product, unless a longer date is supported by stability studies of finished drugs or compounded drug products using the same components and packaging. Shorter dating than set forth in this subsection may be used if it is deemed appropriate in the professional judgment of the responsible pharmacist.

". . . .

"(j) Prior to allowing any drug product to be compounded in a pharmacy, the pharmacist-in-charge shall complete a self-assessment for compounding pharmacies developed by the board. (Incorporated by reference is "Community Pharmacy & Hospital Outpatient Pharmacy Compounding Self-Assessment" Form 17M-39 Rev. 02/12.) That form contains a first section applicable to all compounding, and a second section applicable to sterile injectable compounding. The first section must be completed by the pharmacist-in-charge before any compounding is performed in the pharmacy. The second section must be completed by the pharmacist-in-charge before any sterile injectable compounding is performed in the pharmacy. The applicable sections of the self-assessment shall subsequently be completed before July 1 of each odd-numbered year, within 30 days of the start of a new pharmacist-in-charge, and within 30 days of the issuance of a new pharmacy license. The primary purpose of the self-assessment is to promote compliance through self-examination and education."

24. California Code of Regulations, title 16, section 1735.3 states, in pertinent part:

"(a) For each compounded drug product, the pharmacy records shall include:

"(1) The master formula record.

". . . .

"(d) Pharmacies shall maintain and retain all records required by this article in the pharmacy in a readily retrievable form for at least three years from the date the record was created."

1 25. California Code of Regulations, title 16, section 1735.4(b) states:

2 "A statement that the drug has been compounded by the pharmacy shall be included on the
3 container or on the receipt provided to the patient."

4 26. California Code of Regulations, title 16, section 1735.5 states, in pertinent part:

5 "(a) Any pharmacy engaged in compounding shall maintain a written policy and procedure
6 manual for compounding that establishes procurement procedures, methodologies for the
7 formulation and compounding of drugs, facilities and equipment cleaning, maintenance,
8 operation, and other standard operating procedures related to compounding.

9 "(b) The policy and procedure manual shall be reviewed on an annual basis by the
10 pharmacist-in-charge and shall be updated whenever changes in processes are implemented.

11 "(c) The policy and procedure manual shall include the following

12 "(1) Procedures for notifying staff assigned to compounding duties of any changes in
13 processes or to the policy and procedure manual.

14 "(2) Documentation of a plan for recall of a dispensed compounded drug product
15 where subsequent verification demonstrates the potential for adverse effects with continued use of
16 a compounded drug product.

17 "(3) The procedures for maintaining, storing, calibrating, cleaning, and disinfecting
18 equipment used in compounding, and for training on these procedures as part of the staff training
19 and competency evaluation process.

20 "(4) Documentation of the methodology used to test integrity, potency, quality, and
21 labeled strength of compounded drug products.

22 "(5) Documentation of the methodology used to determine appropriate expiration
23 dates for compounded drug products."

24 27. California Code of Regulations, title 16, section 1735.7 provides, in pertinent part:

25 "(a) Any pharmacy engaged in compounding shall maintain written documentation
26 sufficient to demonstrate that pharmacy personnel have the skills and training required to properly
27 and accurately perform their assigned responsibilities relating to compounding.

28

1 "(b) The pharmacy shall develop and maintain an on-going competency evaluation process
2 for pharmacy personnel involved in compounding, and shall maintain documentation of any and
3 all training related to compounding undertaken by pharmacy personnel.

4 "

5 28. California Code of Regulations, title 16, section 1735.8 provides"

6 "(a) Any pharmacy engaged in compounding shall maintain, as part of its written policies
7 and procedures, a written quality assurance plan designed to monitor and ensure the integrity,
8 potency, quality, and labeled strength of compounded drug products.

9 "(b) The quality assurance plan shall include written procedures for verification,
10 monitoring, and review of the adequacy of the compounding processes and shall also include
11 written documentation of review of those processes by qualified pharmacy personnel.

12 "(c) The quality assurance plan shall include written standards for qualitative and
13 quantitative integrity, potency, quality, and labeled strength analysis of compounded drug
14 products. All qualitative and quantitative analysis reports for compounded drug products shall be
15 retained by the pharmacy and collated with the compounding record and master formula.

16 "(d) The quality assurance plan shall include a written procedure for scheduled action in the
17 event any compounded drug product is ever discovered to be below minimum standards for
18 integrity, potency, quality, or labeled strength."

19 29. California Code of Regulations, title 16, section 1761 states:

20 "(a) No pharmacist shall compound or dispense any prescription which contains any
21 significant error, omission, irregularity, uncertainty, ambiguity or alteration. Upon receipt of such
22 prescription, the pharmacist shall contact the prescriber to obtain the information needed to
23 validate the prescription.

24 "(b) Even after conferring with the prescriber, a pharmacist shall not compound or dispense
25 a controlled substance prescription where the pharmacist knows or has objective reason to know
26 that said prescription was not issued for a legitimate medical purpose."

27 ///

28 ///

1 30. Health and Safety Code section 11153(a) provides:

2 "A prescription for a controlled substance shall only be issued for a legitimate medical
3 purpose by an individual practitioner acting in the usual course of his or her professional practice.
4 The responsibility for the proper prescribing and dispensing of controlled substances is upon the
5 prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the
6 prescription. Except as authorized in this division, the following are not legal prescriptions: (1)
7 an order purporting to be a prescription which is issued not in the usual course of professional
8 treatment or in legitimate and authorized research; or (2) an order for an addict or habitual user of
9 controlled substances, which is issued not in the course of professional treatment or as part of an
10 authorized narcotic treatment program, for the purpose of providing the user with controlled
11 substances, sufficient to keep him or her comfortable by maintaining customary use."

12 31. Health and Safety Code section 11162.1 provides, in pertinent part, that prescription
13 forms shall contain specified security features and be sequentially numbered.

14 32. Health and Safety Code section 11164 provides, in pertinent part, that no person shall
15 fill, compound, or dispense a prescription unless it contains specified information and is made on
16 a controlled substance prescription form as specified in Health and Safety Code section 11162.1.

17 33. Health and Safety Code section 11165(d) requires pharmacies that dispense a
18 schedule II, III, or IV controlled substance (as determined by federal law) to report the quantity of
19 controlled substance, specified information about the prescriber and ultimate user of the
20 controlled substance, and other detailed information to the Department of Justice no later than
21 seven days after dispensing the substance.

22 34. Code of Federal Regulations, title 21, section 1301.75(b) provides:

23 "Controlled substances listed in Schedules II, III, IV, and V shall be stored in a securely
24 locked, substantially constructed cabinet. However, pharmacies and institutional practitioners
25 may disperse such substances throughout the stock of noncontrolled substances in such a manner
26 as to obstruct the theft or diversion of the controlled substances."

27 ///

28 ///

DRUGS

1
2 37. HC/APAP, which refers to hydrocodone mixed with acetaminophen, is available in
3 various dosages (e.g., 10/325mg or 5/500mg), is a Schedule III controlled substance as designated
4 by Health and Safety Code section 11056(e)(4), is a Schedule II controlled substance under
5 federal law, and is a dangerous drug as designated by Code section 4022. It is often referenced by
6 the brand names Lortab, Norco, or Vicodin.

7 38. Oxycodone, sometimes referred to by the brand name Oxycontin, is a Schedule II
8 controlled substance as designated by Health and Safety Code section 11055(b)(1)(M), and a
9 dangerous drug pursuant to Code section 4022.

10 39. Promethazine with codeine is an antihistamine/antitussive, narcotic analgesic, and
11 sleep aid containing codeine, a Schedule V controlled substance as designated by Health and
12 Safety Code section 11058(c)(1), and a dangerous drug as designated by Code section 4022.

13 40. Diazepam, first marketed as Valium, is a Schedule IV controlled substance as
14 designated by Health and Safety Code section 11057(d)(9), and a dangerous drug as designated by
15 Code section 4022.

16 41. Carisoprodol, often referenced by the brand name Soma, has been a Schedule IV
17 controlled substance under federal law since January 11, 2012, and is a dangerous drug as
18 designated by Code section 4022.

19 42. Hydroxyzine is an antihistamine with anxiolytic properties. It is a dangerous drug
20 pursuant to Code section 4022.

21 43. Hydralazine is a vasodilator used to treat hypertension. It is a dangerous drug
22 pursuant to Code section 4022.

23 44. Glipizide is an anti-diabetic drug. It is a dangerous drug pursuant to Code section
24 4022.

25 45. Opana ER is a brand name for the opioid oxymorphone, a Schedule II controlled
26 substance as designated by Health and Safety Code section 11055(b)(1)(N), and a dangerous drug
27 pursuant to Code section 4022.

28 ///

1 46. Clonazepam (Klonopin) is a Schedule IV controlled substance as designated by
2 Health and Safety Code section 11057(d)(7), and is a dangerous drug as designated by Code
3 section 4022.

4 47. Zolpidem tartrate, often referred to by the brand name Ambien, is a Schedule IV
5 controlled substance as designated by Health and Safety Code section 11057(d)(32), and is a
6 dangerous drug as designated by Code section 4022.

7 **I. INVESTIGATION 59086 BACKGROUND**

8 48. On or about October 15, 2013, Respondent High Street refilled a prescription for SJ.¹
9 Respondent Avakian dispensed and/or approved the dispensed prescription. The prescription
10 was for hydroxyzine 25mg tablets. The refill medication bottle depicted this information.

11 49. A few days after taking the medication, SJ began feeling dizzy and experiencing
12 diarrhea and nausea. SJ also felt itchy and suffered from congestion and some difficulty
13 breathing. SJ had previously taken the medication without these effects. SJ's mother took SJ to
14 the emergency room.

15 50. The medication inside the bottle, in fact, was not hydroxyzine 25mg, but hydralazine
16 25mg.

17 ///

18 ///

19 ///

20 ///

21 ///

22 ///

23 ///

24 ///

25 ///

26 ///

27 _____
28 ¹ Full consumer names will be provided in discovery.

1 in an unlocked cabinet. Although the issue was discussed with Respondent Avakian at that time,
2 during a subsequent inspection on July 7, 2013, the cabinet containing the Schedule II controlled
3 substances was again unlocked. When the Board investigators reexamined it later in the day on
4 July 7, it was still unlocked.

5 59. The Board audited Respondent High Street's inventories of selected controlled
6 substances for the period from April 1, 2012, through September 25, 2013. Respondent High
7 Street was unable to account for overages or shortages of the following controlled substances in
8 its September 25, 2013 inventory:

- 9 a) 188 tablets of diazepam 5mg (overage);
- 10 b) 1,602 tablets of diazepam 10mg (overage);
- 11 c) 6,013 tablets of HC/APAP 10/325mg (shortage);
- 12 d) 15 tablets of oxycodone 30mg (shortage);
- 13 e) 600 tablets of HC/APAP 5/500mg (overage);
- 14 f) 398 tablets of HC/APAP 7.5/750mg (overage);
- 15 g) 12,986 units (approximately 27.5 pints) of promethazine with codeine
16 (overage); and
- 17 h) 160 tablets of carisoprodol 350mg (overage).

18 60. Respondent Avakian searched for additional records to reconcile the numbers, but she
19 was unsuccessful. With regard to HC/APAP 10/325mg, for example, Respondent Avakian
20 reported that Respondent High Street had actually received 7,900 less tablets than the invoices
21 indicated, such that Respondent High Street actually had an overage of 1,887 tablets compared to
22 its records. Thereafter, Respondent Avakian informed the Board that she had found another
23 invoice for 1,000, reducing the overage to 887 tablets. Ultimately, however, Respondent Avakian
24 corrected the earlier reports, stating that, having taken additional time to work through the
25 documents, it appeared that Respondent High Street was indeed short 2,613 tablets of HC/APAP
26 10/325mg.

27 ///

28 ///

1 61. Respondent Avakian admitted to the Board that Respondent High Street was not in
2 possession of all of the records of its acquisitions and could not be certain whether Respondent
3 High Street had received all of its controlled substances orders.

4 62. The Board reviewed data provided to the CURES/ Prescription Drug Monitoring
5 Program (PDMP) by other pharmacies to assess Respondent High Street's comparative dispensing
6 practices. The data indicated that out of a sample of 6 pharmacies within 3 miles of Respondent
7 High Street, Respondent High Street filled the highest number of 5 of 6 different controlled
8 substances reviewed, including 1.5 times as many prescriptions for HC/APAP 10/325mg as the
9 second-highest dispensing pharmacy, more than 3 times the number of diazepam 10mg
10 prescriptions of the second-highest dispensing pharmacy, nearly 2.5 times the number of
11 prescriptions for carisoprodol 350mg of the second-highest dispensing pharmacy, nearly 2.5 times
12 the number of prescriptions for HC/APAP 7.5/750mg of the second-highest dispensing pharmacy,
13 and nearly 5 times the number of oxycodone 30mg of the second-highest dispensing pharmacy.

14 63. The Board performed a review of selected prescriptions Respondent High Street had
15 filled between January 1, 2012, and November 2013, as well as related data from PDMP. PDMP
16 data are made available to pharmacists to assist them in making determinations about the
17 legitimacy of controlled substance prescriptions. Respondent Avakian admitted that Respondent
18 High Street had not been using PDMP to make such determinations. Respondent Avakian further
19 admitted that she did not feel it was her job to evaluate diagnoses so only sometimes inquired in
20 that regard, and that she did not assess patients for pain.

21 64. In reviewing the prescriptions, the Board found that many prescriptions for controlled
22 substances had not been reported by Respondent High Street to CURES within the required time
23 frame.

24 65. The Board discovered multiple specific prescriptions for controlled substances that
25 were of questionable legitimacy and/or were clearly illegitimate. Various circumstances (apart
26 from the background circumstances described above) surrounding such prescriptions should have
27 raised red flags for Respondent High Street's pharmacists, such as: the long distance from the
28 customer's residence to Respondent High Street; the long distance the customer had travelled for

1 the visit with the prescriber; the customer's utilization of private payment (cash); the customer's
2 history of pharmacy and/or prescriber shopping; the early timing of the fill request in relation to
3 prior fills at the same or other pharmacies; a customer's use of the pharmacy for only controlled
4 substances; the prescriber's high volume of controlled substance prescriptions, particularly when
5 not a pain specialist or other type of specialist that would explain the volume; inconsistency
6 between the diagnosis and the patient's prescriptions; and/or the combination of medications
7 prescribed.

8 66. Respondent High Street had nonetheless failed to inquire with prescribers regarding
9 the prescriptions, and Respondent High Street filled prescriptions that Respondent High Street
10 had objective reason to know were not issued for a legitimate medical purpose. Of a sample of 35
11 customers' controlled substance prescriptions, the following were the most troubling in this
12 regard, broken down by customer, along with a description of some of the most significant red
13 flags indicating that prescriptions may not have been issued (and/or were not issued) for
14 legitimate medical purposes:

15 **Customer WP**

16 67. During 2012, Respondent High Street dispensed HC/APAP 10/325mg to WP on
17 10/30, 11/26, and 12/24.

18 68. The distances WP travelled raised red flags. WP had travelled 13.9 miles from WP's
19 residence to come to Respondent High Street, and WP had travelled 81.2 miles to see the
20 prescriber of the controlled substances, Dr. C.L. Nate Pettinger (Dr. Pettinger). The distance
21 between the prescriber and Respondent High Street was roughly 92.9 miles.

22 69. Respondent Avakian admitted that she did not know Dr. Pettinger. The Medical
23 Board's website did not identify Dr. Pettinger as a pain specialist. Yet according to data reported
24 by Respondent High Street, Respondent High Street filled 379 controlled substance prescriptions
25 written by Dr. Pettinger during 2012, making Dr. Pettinger Respondent High Street's 5th highest
26 prescriber of controlled substances.

27 70. Available PDMP data suggested that WP was engaged in doctor-shopping and
28 pharmacy-shopping. Specifically:

- 1 A. By the time Respondent High Street filled the 10/30/12 prescription, WP had
2 already obtained HC/APAP 10/325mg prescriptions from 9 different prescribers
3 during 2012. WP had filled these prescriptions at 9 different pharmacies,
4 making Respondent High Street the 10th pharmacy that dispensed HC/APAP
5 10/325mg to WP during calendar year 2012.
- 6 B. By the time Respondent High Street dispensed the 11/26/12 refill, the number
7 of different prescribers providing HC/APAP 10/325mg prescriptions to WP
8 during 2012 had increased to 11. Respondent High Street remained one of 10
9 different pharmacies used by WP in 2012 to fill such prescriptions.
- 10 C. As of the 11/26/12 refill, WP had filled, in the preceding 30 days, HC/APAP
11 10/325mg prescriptions at four different pharmacies. WP had obtained during
12 that 30-day period a total of 146 days worth of HC/APAP 10/325mg. WP had
13 obtained a 20-day supply at Respondent High Street on 10/30/12, a 33-day
14 supply at Safeway on 11/13/12, a 46-day supply at Target on 11/14/12, and a
15 47-day supply at Wal-Mart on 11/21/12. Yet Respondent High Street provided
16 another 20-day supply five days later, on 11/26/12.

17 71. According to Respondent High Street's records, WP filled only controlled substance
18 prescriptions (6 total during the year) when WP came to Respondent High Street. WP private-
19 paid (cash) for all of them.

20 Customer RW

21 72. During 2012, RW obtained carisoprodol 350mg from Respondent High Street on
22 8/23, 11/5, and 12/1.

23 73. The distances RW travelled raised red flags. RW travelled 7 miles from RW's
24 residence to come to Respondent High Street and 87.5 miles to visit the prescriber, Dr. Pettinger.
25 The distance between Respondent High Street and the prescriber was 92.9 miles.

26 74. The 8/23/12 carisoprodol prescription was accompanied by prescriptions, filled the
27 same day at Respondent High Street, for HC/APAP 10/325mg and diazepam 10mg. In
28 combination, these drugs form a version of what is known illicitly as the "trinity" or "holy

1 trinity."² The combination of such drugs, which have overlapping effects, is of dubious medical
2 legitimacy and a significant red flag to a pharmacist. Furthermore, seven days later, on 8/30/12,
3 RW returned to Respondent High Street and filled a prescription for another opioid, Opana ER.

4 75. Available PDMP data showed that by the time Respondent High Street dispensed the
5 8/23/12 carisoprodol prescription, RW had obtained carisoprodol prescriptions from four different
6 prescribers during 2012.

7 76. On September 28, 2012, RW filled prescriptions for HC/APAP 10/325mg and
8 diazepam 10mg at Respondent High Street. Data available on PDMP showed that RW had
9 obtained the third component of the holy trinity elsewhere that month: RW had filled a
10 carisoprodol prescription at Walgreens 7 days earlier.

11 77. On November 5, 2012, RW filled prescriptions for HC/APAP 10/325mg and
12 carisoprodol 350mg at Respondent High Street. PDMP data show that RW had just obtained,
13 four days prior, a prescription for 30 days of Oxycontin, written by a different prescriber and filled
14 at a different pharmacy. Even if that information were not yet available on PDMP at that time,
15 Respondent High Street filled identical prescriptions one month later, on December 1, 2012, and
16 again, RW had just refilled the Oxycontin at another pharmacy.

17 78. By the time Respondent High Street dispensed the 12/1/12 refill, RW had filled 10
18 prescriptions at Respondent High Street, all from Dr. Pettinger, private-paying (cash) \$1,198.95
19 for one of them. All were for controlled substances.

20 Customer KO

21 79. During 2012, KO filled prescriptions for oxycodone 30mg at Respondent High Street
22 on 7/2³ and 8/24. The prescriptions were written by Dr. Tariq Mirza and Dr. Robert Gentile, both
23 of whom worked at Ariba Healthcare Group, Inc., in Fremont.

24 80. The distances KO travelled with regard to these two prescriptions raised red flags.
25 KO travelled 11.6 miles from KO's residence to come to Respondent High Street and 11.8 miles

26 _____
27 ² "The Holy Trinity" or "trinity" is a drug regimen that includes at least one opioid, a
benzodiazepine, and carisoprodol.

28 ³ This prescription was not reported to CURES.

1 in the other direction to visit the prescribers. (The distance from the prescribers to Respondent
2 High Street was roughly 24 miles.)

3 81. Available PDMP data suggested that KO was engaged in doctor-shopping and
4 pharmacy-shopping. Specifically:

5 A. As of the time Respondent High Street filled the 7/2/12 prescription, KO had
6 obtained prescriptions for oxycodone 30mg from three different prescribers
7 during 2012, filling the prescriptions at three different pharmacies other than
8 Respondent High Street. Moreover, KO had obtained a 30-day supply of
9 oxycodone 30mg just 7 days prior, on 6/25/12, at Haller's Pharmacy, along with
10 a 30-day supply of HC/APAP 10/325mg, both of which were written by a
11 different prescriber than the prescription filled by Respondent High Street.

12 B. As of the time Respondent High Street filled the 8/24/12 prescription, KO had
13 obtained prescriptions for oxycodone 30mg from four different prescribers
14 during 2012, filling them at 5 different pharmacies other than Respondent High
15 Street. Moreover, KO had obtained, within the previous 30 days, a 30-day
16 supply at Safeway (on 7/27/12), and another 45-day supply at Walgreens (on
17 8/3/12). Respondent High Street nevertheless dispensed another 30-day supply
18 on 8/24/12.

19 82. KO private-paid (cash) for both of the oxycodone 30mg prescriptions filled at
20 Respondent High Street. KO paid \$209.95 for the 7/2/12 prescription and \$214.95 for the 8/24/12
21 prescription.

22 83. Additionally, KO filled prescriptions at Respondent High Street for HC/APAP
23 10/325mg and diazepam 10mg, together, on 10/29/12, 11/24/12, and 12/24/12. The distances
24 travelled with respect to these prescriptions, too, raised red flags. KO travelled 11.6 miles to
25 come to Respondent High Street and 104 miles to visit the prescriber, Dr. Pettinger, who was
26 located 92.9 miles from Respondent High Street.

27 84. KO obtained a total of 13 prescriptions from Respondent High Street during 2012, 12
28 of which were for controlled substances.

Customer NJ

1
2 85. NJ obtained prescriptions for HC/APAP 10/325mg from Respondent High Street on
3 7/24/2012, 8/2/2012, 9/14/2012, 1/11/2013, 2/7/2013, 3/6/2013⁴, and 6/5/2013. NJ further
4 obtained oxycodone 30mg prescriptions from Respondent High Street on 6/23/2012, 7/24/2012,
5 8/2/2012, 8/29/2012, 9/14/2012, 1/11/2013, and 4/17/2013⁵.

6 86. Several of these prescriptions were written by Dr. Pettinger. For those prescriptions,
7 the distances NJ travelled raised red flags. NJ travelled 96 miles to visit the prescriber, who was
8 92.9 miles from Respondent High Street.

9 87. Some of the prescriptions were written by Dr. Pacita Aducayen. For those
10 prescriptions, too, the distances NJ travelled raised red flags. NJ travelled 7.3 miles to get to
11 Respondent High Street and 39.4 miles to get to the prescriber (who was 34.5 miles from
12 Respondent High Street).

13 88. Available PDMP data suggested that NJ was engaged in doctor-shopping and
14 pharmacy-shopping. By way of illustration, on 9/14/2012, NJ filled prescriptions for oxycodone
15 30mg, HC/APAP 10/325mg, and carisoprodol at Respondent High Street. By that time, NJ had
16 filled prescriptions for oxycodone 30mg at 4 different pharmacies during 2012, and had filled
17 prescriptions for HC/APAP 10/325mg at 6 different pharmacies during 2012. Additionally, as of
18 that date, NJ had filled prescriptions for oxycodone 30mg from 5 different prescribers, and had
19 filled prescriptions for HC/APAP 10/325mg from 5 different prescribers, during 2012.

20 89. NJ presented early and duplicative prescriptions for overlapping short-term opioids.

21 A. By way of illustration, on July 24, 2012, NJ filled a prescription for 160 tablets
22 of oxycodone 30mg (a 20-day supply) and a prescription for 180 tablets of
23 HC/APAP 10/325mg (a 22-day supply) at Respondent High Street.⁶ Nine days
24 later, on August 2, 2012, NJ again returned to Respondent High Street and
25

26
27 ⁴ This prescription was not reported to CURES.

⁵ This prescription was not reported to CURES.

⁶ HC/APAP and oxycodone are both short-acting opioids, overlapping in their effects.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

filled additional prescriptions for 180 tablets of oxycodone 30mg (a 60-day supply) and 180 tablets of HC/APAP 10/325mg (a 45-day supply).

B. PDMP records show that NJ then obtained another 60-day supply of oxycodone 30mg, thirteen days later (on August 15, 2012), at a different pharmacy, as well as a another prescription for HC/APAP 325/10mg. NJ thereafter returned to Respondent High Street on August 29, 2012, and filled another prescription for a 30-day supply of oxycodone 30mg. Even ignoring the parallel HC/APAP prescriptions, as of the time Respondent High Street filled the oxycodone 30mg prescription on August 29, NJ had already obtained 140 days worth of oxycodone 30mg during the preceding 36 days. Of that, 80 days worth (of the 140) were provided by Respondent High Street itself. Respondent High Street nevertheless provided another 30 days worth, on 8/29/12.

90. NJ was not an elderly patient, suggesting long-term, heavy opioid treatment was less likely appropriate from a medical perspective.

91. NJ private-paid (cash) for all of NJ's prescriptions filled at Respondent High Street during 2012, despite the fact that available PDMP data showed that NJ had commercial insurance.

92. Thirteen of fifteen prescriptions filled by NP at Respondent High Street during 2012 were for controlled substances.

Customer SH

93. During 2012, SH obtained prescriptions from Respondent High Street for HC/APAP 10/325mg, oxycodone 30mg, and promethazine with codeine. SH filled prescriptions for all three drugs together on 6/22/2012 and 12/5/2012. The cocktail of drugs was a red flag, as was the overlapping nature of the opioid prescriptions.

94. The distances SH travelled with respect to these prescriptions were also cause for inquiry. SH travelled 14.2 miles to get to Respondent High Street and 108 miles to get to the prescriber, Dr. Pettinger.

///
///

1 95. Available PDMP data showed that SH filled early prescriptions at Respondent High
2 Street:

3 A. Before filling the 6/22/2012 prescription for HC/APAP 10/325mg at
4 Respondent High Street, SH filled HC/APAP 10/325mg prescriptions at other
5 pharmacies on 6/12/2012 (a 12-day supply) and 6/15/2012 (a 30-day supply).
6 Thus, in the ten days prior, SH had obtained 42 days worth of HC/APAP
7 10/325mg from other pharmacies. SH had also, within the same time frame,
8 obtained 30 days worth of oxycodone 30mg from other pharmacies.
9 Respondent High Street nevertheless provided SH an additional 19 days worth
10 of HC/APAP 10/325mg and an additional 30 days worth of oxycodone 30mg,
11 on 6/22/12.

12 B. Respondent High Street filled the 12/5/12 HC/APAP 10/325mg prescription ten
13 days early.

14 96. PDMP data further showed that SH was engaged in pharmacy and prescriber
15 shopping. By the time Respondent High Street filled the 12/5/2012 prescriptions, SH had
16 obtained HC/APAP 10/325mg from 7 different pharmacies and 3 different prescribers during
17 2012, and had obtained oxycodone 30mg from 5 different pharmacies and 4 different prescribers
18 during 2012.

19 97. SH private-paid (cash) for all of the prescriptions filled at Respondent High Street,
20 even though available PDMP data showed that SH had commercial insurance.

21 98. SH obtained only controlled substances from Respondent High Street.

22 **Customer MSJ**

23 99. In 2012 and 2013, Respondent High Street filled multiple prescriptions for MSJ for
24 HC/APAP, diazepam, and carisoprodol. Over the course of 2012 and 2013, MSJ filled enough of
25 these three prescriptions at Respondent High Street to remain consistently, for all intents and
26 purposes, medicated on the holy trinity. Between January 1, 2012, and October 23, 2013, MSJ
27 obtained from Respondent High Street 444 days worth of diazepam, 660 days worth of
28 carisoprodol, and 579 days worth of HC/APAP. Incorporating prescriptions filled by MSJ at

1 other pharmacies, as shown on PDMP, more than enough of these medications were provided to
2 MSJ to remain constantly on the holy trinity.

3 100. MSJ further obtained many of the prescriptions early. By way of illustration:

- 4 A. On April 5, 2012, MSJ filled an original prescription for diazepam 10mg at
5 Respondent High Street (15-day supply), and then filled the refill prescription at
6 Respondent High Street on the same day (15-day supply). MSJ used insurance
7 to pay for the first and then private-paid (cash) for the refill.
- 8 B. On August 8, 2012, MSJ filled a prescription for diazepam 10mg at Respondent
9 High Street (15-day supply). MSJ then obtained from Respondent High Street a
10 refill of that prescription on August 14, 2012 (15-day supply). MSJ used
11 insurance to pay for the original prescription and then private-paid (cash) for the
12 refill. Two days later, on August 16, 2012, MSJ filled another new prescription
13 for diazepam 10mg at Respondent High Street (30-day supply). The
14 prescription was from the same doctor as the first, and MSJ again private-paid
15 (cash). Thus, over a period of eight days, MSJ filled three separate prescription
16 orders for the same controlled substance, all at Respondent High Street.
- 17 C. On May 16, 2012 and May 31, 2012, MSJ filled prescriptions at Respondent
18 High Street for carisoprodol 350mg, each of which were for a 30-day supply.
- 19 D. On August 8, 2012 and August 16, 2012, MSJ filled prescriptions at
20 Respondent High Street for carisoprodol 350mg, each of which were for a 30-
21 day supply.
- 22 E. On March 8, 2013, and March 27, 2013, MSJ filled prescriptions at Respondent
23 High Street for carisoprodol 350mg, each of which were for a 30-day supply.
24 Information on PDMP shows that MSJ then obtained another 30-day supply at a
25 different pharmacy 14 days later, on 4/10/2013, after which MSJ obtained 30-
26 day supplies from Respondent High Street on 5/6/2013, 5/13/2013, 6/6/2013,
27 6/14/2013, 7/2/2013, and 7/27/2013. By the time Respondent High Street filled
28 the 7/27/2013 prescription, MSJ had obtained 210 days worth of carisoprodol

1 350mg over the preceding 141 days (and of that 210, Respondent High Street
2 had itself provided 180). Respondent High Street then provided yet another 30-
3 day supply, on 7/27/2013.

4 F. Respondent High Street filled HC/APAP 10/325mg prescriptions for MSJ on
5 5/16/2012 (30-day supply), followed by a separate prescription from the same
6 prescriber 9 days later, on 5/25/2012 (30-day supply).

7 G. Respondent High Street filled separate HC/APAP 10/325mg prescriptions for
8 MSJ on 8/8/2012 (30-day supply) and 8/16/2012 (30-day supply).

9 H. Respondent High Street filled prescriptions for HC/APAP 10/325mg for MSJ
10 on 3/22/2013 (22-day supply), and then another (30-day supply) 4 days later, on
11 3/27/2013, from a different prescriber. Respondent High Street continued
12 filling HC/APAP 10/325mg prescriptions for MSJ from these two prescribers,
13 providing a 30-day supply on 4/24/2013, a 22-day supply on 5/13/2013, a 22-
14 day supply on 6/6/2013, a 30-day supply on 6/14/2013, a 22-day supply on
15 7/2/2013, and a 22-day supply on 7/26/2013. By the time Respondent High
16 Street filled the 7/26/2013 prescription, MSJ had obtained (from Respondent
17 High Street alone) 178 days worth of HC/APAP 10/325mg over the preceding
18 126 days. Respondent High Street then provided yet another 22-day supply, on
19 7/26/13.

20 101. MSJ obtained 26 controlled prescriptions from Respondent High Street in 2012, and
21 another 25 controlled substance prescriptions from Respondent High Street in 2013.

22 Customer AP

23 102. In 2012 and 2013, Respondent High Street filled multiple prescriptions for AP for
24 drugs that together constitute the holy trinity. Respondent High Street filled prescriptions for
25 HC/APAP 10/325mg, carisoprodol 350mg, and diazepam 10mg, together, on 1/10/2012,
26 2/14/2012, 3/15/2012, 4/17/2012, 5/15/2012, 6/13/2012, 7/18/2012, 8/15/2012⁷, 9/13/2012,

27 ⁷ Respondent High Street filled the HC/APAP and carisoprodol prescriptions on
28 8/15/2012 and filled the diazepam prescription the next day.

1 10/10/2012⁸, 11/8/2012, 12/11/2012, 1/10/2013, 2/7/2013, 3/6/2013, 4/3/2013, 5/1/2013,
2 6/5/2013, and 8/7/2013. In July of 2013, Respondent High Street filled prescriptions for drugs
3 together constituting the holy trinity for AP, with clonazepam in place of diazepam.

4 103. During 2012 and 2013, Respondent High Street also provided AP with sufficient
5 oxycontin to permit continual usage.

6 104. Available PDMP data showed that, during some of this time, AP was also obtaining
7 additional benzodiazepines and HC/APAP at other pharmacies.

8 105. Although AP paid for most of the medication with commercial insurance, AP private
9 paid (cash) for virtually all of the diazepam.

10 **FIFTH CAUSE FOR DISCIPLINE**

11 **AS TO RESPONDENT AVAKIAN**

12 **(Physical Security for Controlled Substances)**

13 106. Respondent Avakian is subject to disciplinary action under Code section 4301(o) and
14 Code of Federal Regulations, title 21, section 1301.75(b), in that, either through her own conduct
15 or inaction, or derivatively as an owner of Respondent High Street or as a Pharmacist-in-Charge
16 under Code section 4113(c) and/or 4036.5, Respondent Avakian directly or indirectly violated, or
17 attempted to violate, or assisted in or abetted a violation of, the statutes or regulations regulating
18 the practice of pharmacy. As described above in "Investigation 56653 Background," Respondent
19 Avakian either failed to store or was indirectly responsible for failing to store controlled
20 substances listed in Schedules II, III, IV, or V in a securely locked, substantially constructed
21 cabinet or in a dispersed manner so as to obstruct theft or diversion.

22 ///

23 ///

24 ///

25 ///

26 ///

27 ⁸ Respondent High Street filled the carisoprodol and diazepam prescriptions on
28 10/10/2012, and filled the HC/APAP prescription the next day.

1 SIXTH CAUSE FOR DISCIPLINE

2 AS TO RESPONDENT HIGH STREET

3 (Physical Security for Controlled Substances)

4 107. Respondent High Street is subject to disciplinary action under Code section 4301(o)
5 and Code of Federal Regulations, title 21, section 1301.75(b), in conjunction with sections 4302
6 and/or 4156 of the Code, in that Respondent High Street directly or indirectly violated, or
7 attempted to violate, or assisted in or abetted a violation of, the statutes or regulations regulating
8 the practice of pharmacy. As discussed above in "Investigation 56653 Background," Respondent
9 High Street failed to store or was indirectly responsible for failing to store controlled substances
10 listed in Schedules II, III, IV, or V in a securely locked, substantially constructed cabinet or in a
11 dispersed manner so as to obstruct theft or diversion.

12 SEVENTH CAUSE FOR DISCIPLINE

13 AS TO RESPONDENT AVAKIAN

14 (Inability to Account for Current Inventory)

15 108. Respondent Avakian is subject to disciplinary action under Code section 4301(o), in
16 conjunction with sections 4081(a) and/or 4332 of the Code and/or California Code of
17 Regulations, title 16, section 1718, in that, either through her own conduct or inaction, or
18 derivatively as an owner of Respondent High Street or as a Pharmacist-in-Charge under Code
19 section 4113(c) and/or 4036.5, Respondent Avakian directly or indirectly violated, or attempted to
20 violate, or assisted in or abetted a violation of, the statutes or regulations regulating the practice of
21 pharmacy. As discussed above in "Investigation 56653 Background," Respondent Avakian failed
22 to keep or was indirectly responsible for failing to keep a current inventory for Respondent High
23 Street, including complete accountability for all dangerous drugs.

24 ///

25 ///

26 ///

27 ///

28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

EIGHTH CAUSE FOR DISCIPLINE

AS TO RESPONDENT HIGH STREET

(Inability to Account for Current Inventory)

109. Respondent High Street is subject to disciplinary action under Code section 4301(o), in conjunction with sections 4081(a) and/or 4332 of the Code and/or California Code of Regulations, title 16, section 1718, and pursuant to sections 4302 and/or 4156 of the Code, in that Respondent High Street directly or indirectly violated, or attempted to violate, or assisted in or abetted a violation of, the statutes or regulations regulating the practice of pharmacy. As discussed above in "Investigation 56653 Background," Respondent High Street failed to keep or was indirectly responsible for failing to keep a current inventory, including complete accountability for all dangerous drugs.

NINTH CAUSE FOR DISCIPLINE

AS TO RESPONDENT AVAKIAN

(Maintenance of Records Available for Inspection)

110. Respondent Avakian is subject to disciplinary action under Code section 4301(o), in conjunction with sections 4081(a) and/or 4332 of the Code, in that, either through her own conduct or inaction, or derivatively as an owner of Respondent High Street or as a Pharmacist-in-Charge under Code section 4113(c) and/or 4036.5, Respondent Avakian directly or indirectly violated, or attempted to violate, or assisted in or abetted a violation of, the statutes or regulations regulating the practice of pharmacy. As discussed above in "Investigation 56653 Background," Respondent Avakian failed to maintain or was indirectly responsible for failing to maintain all records of the acquisition and/or disposition of dangerous drugs available for inspection during business hours and/or to preserve those records for three years from the date they were made.

///

///

///

///

///

1 **TENTH CAUSE FOR DISCIPLINE**

2 **AS TO RESPONDENT HIGH STREET**

3 **(Maintenance of Records Available for Inspection)**

4 111. Respondent High Street is subject to disciplinary action under Code section 4301(o),
5 in conjunction with sections 4081(a) and/or 4332 of the Code, and pursuant to sections 4302
6 and/or 4156 of the Code, in that Respondent High Street directly or indirectly violated, or
7 attempted to violate, or assisted in or abetted a violation of, the statutes or regulations regulating
8 the practice of pharmacy. As discussed above in "Investigation 56653 Background," Respondent
9 High Street failed to maintain or was indirectly responsible for failing to maintain all records of
10 the acquisition and/or disposition of dangerous drugs available for inspection during business
11 hours and/or to preserve those records for three years from the date they were made.

12 **ELEVENTH CAUSE FOR DISCIPLINE**

13 **AS TO RESPONDENT AVAKIAN**

14 **(Corresponding Responsibility)**

15 112. Respondent Avakian is subject to disciplinary action under Code section 4301(o) in
16 conjunction with Health and Safety Code section 11153(a) and/or California Code of Regulations,
17 title 16, section 1761, in that, either through her own conduct or inaction, or derivatively as an
18 owner of Respondent High Street or as a Pharmacist-in-Charge under Code section 4113(c)
19 and/or 4036.5, Respondent Avakian directly or indirectly violated, or attempted to violate, or
20 assisted in or abetted a violation of, the statutes or regulations governing the practice of pharmacy.

21 113. As discussed above in "Investigation 56653 Background," with regard to customers
22 WP, RW, KO, NJ, SH, MSJ, and AP, Respondent Avakian and/or employees of Respondent High
23 Street failed to appropriately exercise the corresponding responsibility to ensure that Respondent
24 High Street only filled prescriptions issued for legitimate medical purposes. Respondent Avakian
25 and/or employees of Respondent High Street failed to contact the prescribers to obtain
26 information to verify the customers' prescriptions. Moreover, in multiple instances, Respondent
27 Avakian and/or employees of Respondent High Street filled prescriptions despite having objective
28 reason to know that said prescriptions were not issued for legitimate medical purposes.

1 114. More specifically, Respondent Avakian and/or employees of Respondent High Street
2 failed to contact the prescriber to verify the customer's prescription and/or filled prescriptions
3 with objective reason to know those prescriptions were not issued for legitimate medical purposes
4 in each of the following cases:

- 5 A. Customer WP: Prescriptions dispensed 10/30/12, 11/26/12, and 12/24/12.
6 B. Customer RW: Prescriptions dispensed 8/23/12, 9/28/12, 11/5/12, and 12/1/12.
7 C. Customer KO: Prescriptions dispensed 7/2/12, 8/24/12, 10/29/12, 11/24/12, and
8 12/24/12.
9 D. Customer NJ: Prescriptions dispensed 6/23/12, 7/24/12, 8/2/12, 8/29/12,
10 9/14/12, 1/11/13, 2/7/13, 3/6/13, 4/17/13, and 6/5/13.
11 E. Customer SH: Prescriptions dispensed 6/22/12 and 12/5/12.
12 F. Customer MSJ: Prescriptions dispensed 4/5/12, 5/16/12, 5/25/12, 5/31/12,
13 8/8/12, 8/14/12, 8/16/12, 3/8/13, 3/22/13, 3/27/13, 4/24/13, 5/6/13, 5/13/13,
14 6/6/13, 6/14/13, 7/2/13, 7/26/13, and 7/27/13.
15 G. Customer AP: Prescriptions dispensed 1/10/12, 2/14/12, 3/15/12, 4/17/12,
16 5/15/12, 6/13/12, 7/18/12, 8/15/12, 9/13/12, 10/10/12, 11/8/12, 12/11/12,
17 1/10/13, 2/7/13, 3/6/13, 4/3/13, 5/1/13, 6/5/13, 7/10/13, 7/23/13, and 8/7/13.

18 **TWELFTH CAUSE FOR DISCIPLINE**

19 **AS TO RESPONDENT HIGH STREET**

20 **(Corresponding Responsibility)**

21 115. Respondent High Street is subject to disciplinary action under Code section 4301(o),
22 in conjunction with Health and Safety Code section 11153(a) and/or California Code of
23 Regulations, title 16, section 1761, and pursuant to sections 4302 and/or 4156 of the Code, in that
24 Respondent High Street directly or indirectly violated, or attempted to violate, or assisted in or
25 abetted a violation of, the statutes or regulations regulating the practice of pharmacy.

26 116. As discussed above in "Investigation 56653 Background," with regard to the
27 prescriptions specified above in the Eleventh Cause for Discipline for customers WP, RW, KO,
28 NJ, SH, MSJ, and AP, Respondent Avakian and/or employees of Respondent High Street failed to

1 appropriately exercise the corresponding responsibility to ensure that Respondent High Street
2 only filled prescriptions issued for legitimate medical purposes. Respondent Avakian and/or
3 employees of Respondent High Street failed to contact the prescribers to obtain information to
4 verify the customers' prescriptions. Moreover, in multiple instances, Respondent Avakian and/or
5 employees of Respondent High Street filled prescriptions despite having objective reason to know
6 that said prescriptions were not issued for legitimate medical purposes.

7 **THIRTEENTH CAUSE FOR DISCIPLINE**

8 **AS TO RESPONDENT AVAKIAN**

9 **(Unprofessional Conduct - Corresponding Responsibility)**

10 117. Respondent Avakian is subject to disciplinary action under Code sections 4301 and
11 4306.5(b) in that Respondent Avakian engaged in unprofessional conduct. The circumstances are
12 described above in the Eleventh Cause for Discipline and "Investigation 56653 Background."

13 **FOURTEENTH CAUSE FOR DISCIPLINE**

14 **AS TO RESPONDENT HIGH STREET**

15 **(Unprofessional Conduct - Corresponding Responsibility)**

16 118. Respondent High Street is subject to disciplinary action under Code sections 4301 and
17 4306.5, pursuant to sections 4302 and/or 4156 of the Code, in that Respondent High Street
18 engaged in unprofessional conduct. The circumstances are described above in the Eleventh Cause
19 for Discipline, Twelfth Cause for Discipline, and "Investigation 56653 Background."

20 **FIFTEENTH CAUSE FOR DISCIPLINE**

21 **AS TO RESPONDENT AVAKIAN**

22 **(CURES Reporting)**

23 119. Respondent Avakian is subject to disciplinary action under Code section 4301(o), in
24 conjunction with Health and Safety Code section 11165(d), in that, either through her own
25 conduct or inaction, or derivatively as an owner of Respondent High Street or as a Pharmacist-in-
26 Charge under Code section 4113(c) and/or 4036.5, Respondent Avakian directly or indirectly
27 violated, or attempted to violate, or assisted in or abetted a violation of, the statutes or regulations
28 regulating the practice of pharmacy.

1 120. Respondent Avakian and/or employees of Respondent High Street failed to report the
2 following controlled substance prescriptions to the Department of Justice (CURES system) within
3 seven days after dispensing the medication:

- 4 a) Customer LE, RX# 827293, filled 7/12/2012, for carisoprodol 350mg.
- 5 b) Customer DE, RX# 828599, filled 7/24/2012, for carisoprodol 350mg.
- 6 c) Customer NG, RX# 824495, filled 6/21/2012, for carisoprodol 350mg.
- 7 d) Customer NG, RX# 829818, filled 8/2/2012, for carisoprodol 350mg.
- 8 e) Customer NJ, RX# 828621, filled 7/24/2012, for carisoprodol 350mg.
- 9 f) Customer NJ, RX# 829811, filled 8/2/2012, for carisoprodol 350mg.
- 10 g) Customer NJ, RX# C847619, filled 3/6/2013, for HC/APAP 10/325mg.
- 11 h) Customer EJ, RX# C823540, filled 7/6/2012, for HC/APAP 10/325mg.
- 12 i) Customer EJ, RX# 823514, filled 6/14/2012, for carisoprodol 350mg.
- 13 j) Customer EJ, RX# 823514, filled 7/10/2012, for carisoprodol 350mg.
- 14 k) Customer EJ, RX# 823514, filled 8/8/2012, for carisoprodol 350mg.
- 15 l) Customer DM, RX# C826387, filled 7/6/2012, for HC/APAP 10/325mg.
- 16 m) Customer DM, RX# 826388, filled 7/6/2012, for carisoprodol 350mg.
- 17 n) Customer DM, RX# 826388, filled 7/17/2012, for carisoprodol 350mg.
- 18 o) Customer DM, RX# 826388, filled 7/31/2012, for carisoprodol 350mg.
- 19 p) Customer DM, RX# C841834, filled 12/11/2012, for HC/APAP 10/325mg.
- 20 q) Customer DM, RX# C841835, filled 1/16/2013, for carisoprodol 350mg.
- 21 r) Customer KO, RX# N825863, filled 7/2/2012, for oxycodone 30mg.
- 22 s) Customer KO, RX# 825865, filled 7/2/2012, for carisoprodol 350mg.
- 23 t) Customer KO, RX# C853886, filled 3/6/2013, for zolpidem 10mg.
- 24 u) Customer RP, RX# C822701, filled 7/2/2012, for diazepam 10mg.
- 25 v) Customer BP, RX# 826865, filled 7/10/2012, for carisoprodol 350mg.
- 26 w) Customer BP, RX# C842613, filled 12/13/2012, for HC/APAP 10/325mg.
- 27 x) Customer BP, RX# C842613, filled 1/15/2013, for HC/APAP 10/325mg.
- 28 y) Customer KS, RX# N844719, filled 12/13/2012, for oxycodone 30mg.

- 1 z) Customer ET, RX# C826211, filed 7/5/2012, for HC/APAP 10/325mg.
- 2 aa) Customer ET, RX# 826212, filed 7/5/2012, for carisoprodol 350mg.
- 3 bb) Customer ET, RX# 830129, filed 8/4/2012, for carisoprodol 350mg.
- 4 cc) Customer AV, RX# C826541, filed 7/6/2012, for HC/APAP 10/325mg.
- 5 dd) Customer AV, RX# C826542, filed 7/6/2012, for diazepam 10mg.
- 6 ee) Customer BW, RX# C854312, filed 3/9/2013, for HC/APAP 10/325mg.
- 7 ff) Customer BW, RX# C854313, filed 3/9/2013, for alprazolam 2mg.
- 8 gg) Customer AW, RX# 830141, filed 8/4/2012, for carisoprodol 350mg.
- 9 hh) Customer AW, RX# 830141, filed 8/14/2012, for carisoprodol 350mg.

SIXTEENTH CAUSE FOR DISCIPLINE

AS TO RESPONDENT HIGH STREET

(CURES Reporting)

13 121. Respondent High Street is subject to disciplinary action under Code section 4301(o)
 14 and Health and Safety Code section 11165(d), in conjunction with sections 4302 and/or 4156 of
 15 the Code, in that Respondent High Street directly or indirectly violated, or attempted to violate, or
 16 assisted in or abetted a violation of, the statutes or regulations regulating the practice of pharmacy.
 17 Respondent High Street, Respondent Avakian, and/or employees of Respondent High Street
 18 failed to report the controlled substance prescriptions listed above in the Fifteenth Cause for
 19 Discipline to the Department of Justice (CURES system) within seven days after dispensing the
 20 medication.

21 ///

22 ///

23 ///

24 ///

25 ///

26 ///

27 ///

28 ///

1 **SEVENTEENTH CAUSE FOR DISCIPLINE**

2 **AS TO RESPONDENT AVAKIAN**

3 **(Duty to Consult)**

4 122. Respondent Avakian is subject to disciplinary action under Code section 4301(o), in
5 conjunction with California Code of Regulations, title 16, section 1707.2, in that, either through
6 her own conduct or inaction, or derivatively as an owner of Respondent High Street or as a
7 Pharmacist-in-Charge under Code section 4113(c) and/or 4036.5, Respondent Avakian directly or
8 indirectly violated, or attempted to violate, or assisted in or abetted a violation of, the statutes or
9 regulations regulating the practice of pharmacy.

10 123. Specifically, on or about July 2, 2013, as witnessed during the Board's inspection,
11 Respondent High Street delivered prescriptions to patients that were not present in the pharmacy
12 without including written notice to the patients of their right to consultation. Moreover, pharmacy
13 staff of Respondent High Street were observed screening for consultations at the pharmacy
14 counter.

15 **EIGHTEENTH CAUSE FOR DISCIPLINE**

16 **AS TO RESPONDENT HIGH STREET**

17 **(Duty to Consult)**

18 124. Respondent High Street is subject to disciplinary action under Code section 4301(o)
19 and California Code of Regulations, title 16, section 1707.2, in conjunction with sections 4302
20 and/or 4156 of the Code, in that Respondent High Street directly or indirectly violated, or
21 attempted to violate, or assisted in or abetted a violation of, the statutes or regulations regulating
22 the practice of pharmacy.

23 125. Specifically, on or about July 2, 2013, as witnessed during the Board's inspection,
24 Respondent High Street delivered prescriptions to patients that were not present in the pharmacy
25 without including written notice to the patients of their right to consultation. Moreover, pharmacy
26 staff of Respondent High Street were observed screening for consultations at the pharmacy
27 counter.

28 ///

1 **IV. INVESTIGATION 48413 BACKGROUND**

2 126. On or about May 11, 2011, Respondent Marinai, while working as a pharmacist at
3 High Street, dispensed two prescriptions for controlled substances (RX# 781216 and RX#
4 781217) that were written on a prescription form lacking required security elements. Specifically,
5 the prescription form lacked a description of the security features, quantity check-off boxes with
6 spaces for unit designation, notice that the prescription is void if the number of drugs prescribed is
7 not noted, sequential numbering, refill check-boxes, and check-boxes for orders not to substitute.

8 127. Despite the lacking security elements, Respondent Marinai did not call the prescriber
9 to verify the validity of the prescriptions. The prescriptions were not, in fact, valid.

10 **NINETEENTH CAUSE FOR DISCIPLINE**

11 **AS TO RESPONDENT MARINAI**

12 **(Erroneous Prescription)**

13 128. Respondent Marinai is subject to disciplinary action under Code section 4301(o) and
14 Health and Safety Code sections 11164 and 11162.1, in that Respondent Marinai directly or
15 indirectly violated, or attempted to violate, or assisted in or abetted a violation of, the statutes or
16 regulations regulating the practice of pharmacy. As discussed above in "Investigation 48413
17 Background," Respondent Marinai dispensed controlled substances based on a prescription
18 lacking required security elements.

19 **TWENTIETH CAUSE FOR DISCIPLINE**

20 **AS TO RESPONDENT HIGH STREET**

21 **(Erroneous Prescription)**

22 129. Respondent High Street is subject to disciplinary action under Code section 4301(o)
23 and Health and Safety Code sections 11164 and 11162.1, in conjunction with section 4156 of the
24 Code, in that Respondent High Street directly or indirectly violated, or attempted to violate, or
25 assisted in or abetted a violation of, the statutes or regulations regulating the practice of pharmacy.
26 As discussed above in "Investigation 48413 Background," Respondent High Street dispensed
27 controlled substances based on a prescription lacking required security elements.

28 ///

1 **TWENTY-FIRST CAUSE FOR DISCIPLINE**

2 **AS TO RESPONDENT MARINAI**

3 **(Corresponding Responsibility)**

4 130. Respondent Marinai is subject to disciplinary action under Code section 4301(o), in
5 conjunction with Health and Safety Code section 11153(a) and/or California Code of Regulations,
6 title 16, section 1761(a), in that Respondent Marinai directly or indirectly violated, or attempted
7 to violate, or assisted in or abetted a violation of, the statutes or regulations governing the practice
8 of pharmacy. As discussed above in "Investigation 48413 Background," Respondent Marinai
9 failed to exercise the pharmacist's corresponding responsibility to ensure controlled substances are
10 dispensed only for a legitimate medical purpose. Respondent Marinai failed to contact the
11 prescriber of controlled substance prescriptions RX# 781216 and RX# 781217, despite the
12 prescription form's significant omission and/or irregularity.

13 **TWENTY-SECOND CAUSE FOR DISCIPLINE**

14 **AS TO RESPONDENT HIGH STREET**

15 **(Corresponding Responsibility)**

16 131. Respondent High Street is subject to disciplinary action under Code section 4301(o),
17 in conjunction with Health and Safety Code section 11153(a) and/or California Code of
18 Regulations, title 16, section 1761(a), and pursuant to section 4156 of the Code, in that
19 Respondent High Street directly or indirectly violated, or attempted to violate, or assisted in or
20 abetted a violation of, the statutes or regulations regulating the practice of pharmacy. As
21 discussed above in "Investigation 48413 Background," Respondent High Street and/or its
22 pharmacist failed to exercise the corresponding responsibility to ensure controlled substances are
23 dispensed only for a legitimate medical purpose. Respondent High Street and/or its pharmacist
24 failed to contact the prescriber of controlled substance prescriptions RX# 781216 and RX#
25 781217, despite the prescription form's significant omission and/or irregularity.

26 ///

27 ///

28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

TWENTY-THIRD CAUSE FOR DISCIPLINE

AS TO RESPONDENT MARINAI

(Unprofessional Conduct - Corresponding Responsibility)

132. Respondent Marinai is subject to disciplinary action under Code sections 4301 and 4306.5(b) in that Respondent Marinai engaged in unprofessional conduct. The circumstances are described above in the Nineteenth Cause for Discipline and "Investigation 48413 Background."

TWENTY-FOURTH CAUSE FOR DISCIPLINE

AS TO RESPONDENT HIGH STREET

(Unprofessional Conduct - Corresponding Responsibility)

133. Respondent High Street is subject to disciplinary action under Code sections 4301 and 4306.5(b), and pursuant to section 4156 of the Code, in that Respondent High Street engaged in unprofessional conduct. The circumstances are described above in the Twentieth Cause for Discipline and "Investigation 48413 Background."

IV. INVESTIGATION 66051 BACKGROUND

134. On September 14, 2015, the Board inspected Respondent High Street. The inspector found the pharmacy to be dusty, cluttered, and unclean. There were spiders hanging from the wall, a dog bowl at the sink, and ice cream and other food in the pharmacy freezer. No hot water was available.

135. The controlled substances were stored in a locked cabinet. However, the key to the locked cabinet was in an unlocked drawer accessible to non-pharmacist, ancillary staff.

136. The most recent Drug Enforcement Agency Biennial Controlled Substance Inventory performed by Respondent High Street was on November 14, 2013. However, no count had been recorded for HC/APAP 10/325mg or various other controlled substances.

137. The most recent Community Pharmacy Self-Assessment that was completed for Respondent High Street was performed on November 14, 2013. It had not been signed or dated. No subsequent Community Pharmacy Self-Assessment had been performed.

///

///

1 138. Respondent High Street performed some compounding. A Compounding Self-
2 Assessment had been performed and signed on November 14, 2013. No subsequent
3 Compounding Self-Assessment had been performed.

4 139. Respondent High Street had no master formulas for the drug products it compounded.
5 Nor did Respondent High Street have policies and procedures for compounding, a quality
6 assurance plan for compounding, or a training plan or competency evaluation process for
7 personnel engaged in compounding. Furthermore, records revealed that Respondent High Street
8 had given "beyond use dates" to drug products that were in excess of 180 days from the date of
9 compounding. For example, compound serial numbers 915871, 923110, and 938310 contained
10 such excessively late "beyond use dates." Additionally, Respondent High Street had failed to
11 include on the container or receipt of compounded drug products that were provided to customers
12 a statement that the drug product had been compounded by the pharmacy.

13 140. The Board performed an audit of Respondent High Street's HC/APAP 10/325mg
14 inventory for the period between September 26, 2013 and September 14, 2015. The audit
15 discovered that Respondent High Street could not account for the absence of 870 tablets.

16 **TWENTY-FIFTH CAUSE FOR DISCIPLINE**

17 **AS TO RESPONDENT AVAKIAN**

18 **(Physical Security for Controlled Substances)**

19 141. Respondent Avakian is subject to disciplinary action under Code section 4301(o) and
20 Code of Federal Regulations, title 21, section 1301.75(b), in that, either through her own conduct
21 or inaction, or derivatively as an owner of Respondent High Street or as a Pharmacist-in-Charge
22 under Code section 4113(c) and/or 4036.5, Respondent Avakian directly or indirectly violated, or
23 attempted to violate, or assisted in or abetted a violation of, the statutes and regulations regulating
24 the practice of pharmacy. As described above in "Investigation 66051 Background," Respondent
25 Avakian either failed to store or was indirectly responsible for failing to store controlled
26 substances listed in Schedules II, III, IV, or V in a securely locked, substantially constructed
27 cabinet or in a dispersed manner so as to obstruct theft or diversion.

28 ///

1 **TWENTY-SIXTH CAUSE FOR DISCIPLINE**

2 **AS TO RESPONDENT HIGH STREET**

3 **(Physical Security for Controlled Substances)**

4 142. Respondent High Street is subject to disciplinary action under Code section 4301(o)
5 and Code of Federal Regulations, title 21, section 1301.75(b), in conjunction with sections 4302
6 and/or 4156 of the Code, in that Respondent High Street directly or indirectly violated, or
7 attempted to violate, or assisted in or abetted a violation of, the statutes or regulations regulating
8 the practice of pharmacy. As discussed above in "Investigation 66051 Background," Respondent
9 High Street failed to store or was indirectly responsible for failing to store controlled substances
10 listed in Schedules II, III, IV, or V in a securely locked, substantially constructed cabinet or in a
11 dispersed manner so as to obstruct theft or diversion.

12 **TWENTY-SEVENTH CAUSE FOR DISCIPLINE**

13 **AS TO RESPONDENT AVAKIAN**

14 **(Inability to Account for Current Inventory)**

15 143. Respondent Avakian is subject to disciplinary action under Code section 4301(o), in
16 conjunction with sections 4081(a) and/or 4332 of the Code and/or California Code of
17 Regulations, title 16, section 1718, in that, either through her own conduct or inaction, or
18 derivatively as an owner of Respondent High Street or as a Pharmacist-in-Charge under Code
19 section 4113(c) and/or 4036.5, Respondent Avakian directly or indirectly violated, or attempted to
20 violate, or assisted in or abetted a violation of, the statutes or regulations regulating the practice
21 of pharmacy. As discussed above in "Investigation 66051 Background," Respondent Avakian
22 failed to keep or was indirectly responsible for failing to keep a current inventory for Respondent
23 High Street, including complete accountability for all dangerous drugs.

24 ///

25 ///

26 ///

27 ///

28 ///

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

TWENTY-EIGHTH CAUSE FOR DISCIPLINE

AS TO RESPONDENT HIGH STREET

(Inability to Account for Current Inventory)

144. Respondent High Street is subject to disciplinary action under Code section 4301(o), in conjunction with sections 4081(a) and/or 4332 of the Code and/or California Code of Regulations, title 16, section 1718, and pursuant to sections 4302 and/or 4156 of the Code, in that Respondent High Street directly or indirectly violated, or attempted to violate, or assisted in or abetted a violation of, the statutes or regulations regulating the practice of pharmacy. As discussed above in "Investigation 66051 Background," Respondent High Street failed to keep or was indirectly responsible for failing to keep a current inventory, including complete accountability for all dangerous drugs.

TWENTY-NINTH CAUSE FOR DISCIPLINE

AS TO RESPONDENT AVAKIAN

(Operational Standards)

145. Respondent Avakian is subject to disciplinary action under Code section 4301(o) and California Code of Regulations, title 16, section 1714(c), in that, either through her own conduct or inaction, or derivatively as an owner of Respondent High Street or as a Pharmacist-in-Charge under Code section 4113(c) and/or 4036.5, Respondent Avakian directly or indirectly violated, or attempted to violate, or assisted in or abetted a violation of, the statutes or regulations regulating the practice of pharmacy. As discussed above in "Investigation 66051 Background," upon inspection Respondent High Street was unclean, was not free from insects, and was not equipped with hot water.

THIRTIETH CAUSE FOR DISCIPLINE

AS TO RESPONDENT HIGH STREET

(Operational Standards)

146. Respondent High Street is subject to disciplinary action under Code section 4301(o) and California Code of Regulations, title 16, section 1714(c), in conjunction with sections 4302 and/or 4156 of the Code, in that Respondent High Street directly or indirectly violated, or

1 attempted to violate, or assisted in or abetted a violation of, the statutes or regulations regulating
2 the practice of pharmacy. As discussed above in "Investigation 66051 Background," upon
3 inspection Respondent High Street was unclean, was not free from insects, and was not equipped
4 with hot water.

5 **THIRTY-FIRST CAUSE FOR DISCIPLINE**

6 **AS TO RESPONDENT AVAKIAN**

7 **(Pharmacy Self-Assessment)**

8 147. Respondent Avakian is subject to disciplinary action under Code section 4301(o) and
9 California Code of Regulations, title 16, section 1715(a), in that, either through her own conduct
10 or inaction, or derivatively as an owner of Respondent High Street or as a Pharmacist-in-Charge
11 under Code section 4113(c) and/or 4036.5, Respondent Avakian directly or indirectly violated, or
12 attempted to violate, or assisted in or abetted a violation of, the statutes or regulations regulating
13 the practice of pharmacy. As discussed above in "Investigation 66051 Background," Respondent
14 Avakian failed to complete a self-assessment of Respondent High Street's compliance with
15 federal and state pharmacy law before July 1 of every odd-numbered year.

16 **THIRTY-SECOND CAUSE FOR DISCIPLINE**

17 **AS TO RESPONDENT HIGH STREET**

18 **(Pharmacy Self-Assessment)**

19 148. Respondent High Street is subject to disciplinary action under Code section 4301(o)
20 and California Code of Regulations, title 16, section 1715(a), in conjunction with sections 4302
21 and/or 4156 of the Code, in that Respondent High Street directly or indirectly violated, or
22 attempted to violate, or assisted in or abetted a violation of, the statutes or regulations regulating
23 the practice of pharmacy. As discussed above in "Investigation 66051 Background," Respondent
24 Avakian, as PIC, an officer, and an owner of Respondent High Street, failed to complete a self-
25 assessment of Respondent High Street's compliance with federal and state pharmacy law before
26 July 1 of every odd-numbered year.

27 ///

28 ///

1 **THIRTY-THIRD CAUSE FOR DISCIPLINE**

2 **AS TO RESPONDENT AVAKIAN**

3 **(Compounding Without Written Master Formula Record)**

4 149. Respondent Avakian is subject to disciplinary action under Code section 4301(o) and
5 California Code of Regulations, title 16, section 1735.2(d) and/or 1735.3, in that, either through
6 her own conduct or inaction, or derivatively as an owner of Respondent High Street or as a
7 Pharmacist-in-Charge under Code section 4113(c) and/or 4036.5, Respondent Avakian directly or
8 indirectly violated, or attempted to violate, or assisted in or abetted a violation of, the statutes or
9 regulations regulating the practice of pharmacy. As discussed above in "Investigation 66051
10 Background," Respondent Avakian failed to ensure that a master formula record was prepared,
11 including all of the required elements, prior to Respondent High Street compounding drug
12 products. Furthermore, Respondent Avakian failed to ensure that Respondent High Street's
13 pharmacy records included, for at least three years from the date of record creation, those master
14 formula records.

15 **THIRTY-FOURTH CAUSE FOR DISCIPLINE**

16 **AS TO RESPONDENT HIGH STREET**

17 **(Compounding Without Written Master Formula Record)**

18 150. Respondent High Street is subject to disciplinary action under Code section 4301(o)
19 and California Code of Regulations, title 16, section 1735.2(d) and/or 1735.3, in conjunction with
20 sections 4302 and/or 4156 of the Code, in that Respondent High Street directly or indirectly
21 violated, or attempted to violate, or assisted in or abetted a violation of, the statutes or regulations
22 regulating the practice of pharmacy. As discussed above in "Investigation 66051 Background,"
23 Respondent High Street compounded drug products without first preparing a master formula
24 record for each such drug product. Furthermore, Respondent High Street failed to retain, for at
25 least three years from the date of record creation, those master formula records.

26 ///

27 ///

28 ///

1 **THIRTY-FIFTH CAUSE FOR DISCIPLINE**

2 **AS TO RESPONDENT AVAKIAN**

3 **(Improper Compounding "Beyond Use Dates")**

4 151. Respondent Avakian is subject to disciplinary action under Code section 4301(o) and
5 California Code of Regulations, title 16, section 1735.2(h), in that, either through her own
6 conduct or inaction, or derivatively as an owner of Respondent High Street or as a Pharmacist-in-
7 Charge under Code section 4113(c) and/or 4036.5, Respondent Avakian directly or indirectly
8 violated, or attempted to violate, or assisted in or abetted a violation of, the statutes or regulations
9 regulating the practice of pharmacy. As discussed above in "Investigation 66051 Background,"
10 Respondent Avakian failed to ensure that Respondent High Street gave "beyond use dates" not
11 exceeding 180 days from preparation of compounded drug products.

12 **THIRTY-SIXTH CAUSE FOR DISCIPLINE**

13 **AS TO RESPONDENT HIGH STREET**

14 **(Improper Compounding "Beyond Use Dates")**

15 152. Respondent High Street is subject to disciplinary action under Code section 4301(o)
16 and California Code of Regulations, title 16, section 1735.2(h), in conjunction with sections 4302
17 and/or 4156 of the Code, in that Respondent High Street directly or indirectly violated, or
18 attempted to violate, or assisted in or abetted a violation of, the statutes or regulations regulating
19 the practice of pharmacy. As discussed above in "Investigation 66051 Background," Respondent
20 High Street gave "beyond use dates" exceeding 180 days from preparation of compounded drug
21 products.

22 **THIRTY-SEVENTH CAUSE FOR DISCIPLINE**

23 **AS TO RESPONDENT AVAKIAN**

24 **(Compounding Self-Assessment)**

25 153. Respondent Avakian is subject to disciplinary action under Code section 4301(o) and
26 California Code of Regulations, title 16, section 1735.2(j), in that, either through her own conduct
27 or inaction, or derivatively as an owner of Respondent High Street or as a Pharmacist-in-Charge
28 under Code section 4113(c) and/or 4036.5, Respondent Avakian directly or indirectly violated, or

1 attempted to violate, or assisted in or abetted a violation of, the statutes or regulations regulating
2 the practice of pharmacy. As discussed above in "Investigation 66051 Background," Respondent
3 Avakian failed to complete a self-assessment for compounding pharmacies prior to allowing a
4 drug product to be compounded in the pharmacy.

5 **THIRTY-EIGHTH CAUSE FOR DISCIPLINE**

6 **AS TO RESPONDENT HIGH STREET**

7 **(Compounding Self-Assessment)**

8 154. Respondent High Street is subject to disciplinary action under Code section 4301(o)
9 and California Code of Regulations, title 16, section 1735.2(j), in conjunction with sections 4302
10 and/or 4156 of the Code, in that Respondent High Street directly or indirectly violated, or
11 attempted to violate, or assisted in or abetted a violation of, the statutes or regulations regulating
12 the practice of pharmacy. As discussed above in "Investigation 66051 Background," Respondent
13 Avakian, as PIC, an officer, and an owner of Respondent High Street, failed to complete a self-
14 assessment for compounding pharmacies prior to allowing a drug product to be compounded in
15 the pharmacy.

16 **THIRTY-NINTH CAUSE FOR DISCIPLINE**

17 **AS TO RESPONDENT AVAKIAN**

18 **(Failure to Provide Required Compounding Notice)**

19 155. Respondent Avakian is subject to disciplinary action under Code section 4301(o) and
20 California Code of Regulations, title 16, section 1735.4(b), in that, either through her own
21 conduct or inaction, or derivatively as an owner of Respondent High Street or as a Pharmacist-in-
22 Charge under Code section 4113(c) and/or 4036.5, Respondent Avakian directly or indirectly
23 violated, or attempted to violate, or assisted in or abetted a violation of, the statutes or regulations
24 regulating the practice of pharmacy. As discussed above in "Investigation 66051 Background,"
25 Respondent Avakian failed to ensure that a statement that the drug product was compounded by
26 the pharmacy was included on either the container or receipt provided to the patient for each
27 compounded drug product.

28 ///

1 **FORTIETH CAUSE FOR DISCIPLINE**

2 **AS TO RESPONDENT HIGH STREET**

3 **(Failure to Provide Required Compounding Notice)**

4 156. Respondent High Street is subject to disciplinary action under Code section 4301(o)
5 and California Code of Regulations, title 16, section 1735.4(b), in conjunction with sections 4302
6 and/or 4156 of the Code, in that Respondent High Street directly or indirectly violated, or
7 attempted to violate, or assisted in or abetted a violation of, the statutes or regulations regulating
8 the practice of pharmacy. As discussed above in "Investigation 66051 Background," Respondent
9 High Street failed to provide a statement that the drug product was compounded by the pharmacy
10 on either the container or receipt provided to the patient for each compounded drug product.

11 **FORTY-FIRST CAUSE FOR DISCIPLINE**

12 **AS TO RESPONDENT AVAKIAN**

13 **(Failure to Maintain Compounding Policy/Procedure Manual)**

14 157. Respondent Avakian is subject to disciplinary action under Code section 4301(o) and
15 California Code of Regulations, title 16, section 1735.5, in that, either through her own conduct or
16 inaction, or derivatively as an owner of Respondent High Street or as a Pharmacist-in-Charge
17 under Code section 4113(c) and/or 4036.5, Respondent Avakian directly or indirectly violated, or
18 attempted to violate, or assisted in or abetted a violation of, the statutes or regulations regulating
19 the practice of pharmacy. As discussed above in "Investigation 66051 Background," Respondent
20 Avakian failed to ensure that Respondent High Street maintained a written policy and procedure
21 manual for compounding containing the required information. Furthermore, Respondent Avakian
22 failed to review any such manual on an annual basis.

23 **FORTY-SECOND CAUSE FOR DISCIPLINE**

24 **AS TO RESPONDENT HIGH STREET**

25 **(Failure to Maintain Compounding Policy/Procedure Manual)**

26 158. Respondent High Street is subject to disciplinary action under Code section 4301(o)
27 and California Code of Regulations, title 16, section 1735.5, in conjunction with sections 4302
28 and/or 4156 of the Code, in that Respondent High Street directly or indirectly violated, or

1 attempted to violate, or assisted in or abetted a violation of, the statutes or regulations regulating
2 the practice of pharmacy. As discussed above in "Investigation 66051 Background," Respondent
3 High Street failed to maintain a written policy and procedure manual for compounding containing
4 the required information. Furthermore, Respondent Avakian, as PIC, an officer, and owner of
5 Respondent High Street, failed to review any such manual on an annual basis.

6 **FORTY-THIRD CAUSE FOR DISCIPLINE**

7 **AS TO RESPONDENT AVAKIAN**

8 **(Failure to Maintain Compounding Training Documentation and Evaluation Process)**

9 159. Respondent Avakian is subject to disciplinary action under Code section 4301(o) in
10 conjunction with California Code of Regulations, title 16, section 1735.7(a) and/or (b), in that,
11 either through her own conduct or inaction, or derivatively as an owner of Respondent High Street
12 or as a Pharmacist-in-Charge under Code section 4113(c) and/or 4036.5, Respondent Avakian
13 directly or indirectly violated, or attempted to violate, or assisted in or abetted a violation of, the
14 statutes or regulations regulating the practice of pharmacy. As discussed above in "Investigation
15 66051 Background," Respondent Avakian failed to ensure that Respondent High Street
16 maintained written documentation, including documentation of trainings, demonstrating that
17 pharmacy personnel have the skills and training to accurately perform their assigned
18 responsibilities relating to compounding. Respondent Avakian further failed to ensure that
19 Respondent High Street developed and maintained an on-going competency evaluation process
20 for pharmacy personnel involved in compounding, including documentation of trainings.

21 **FORTY-FORTH CAUSE FOR DISCIPLINE**

22 **AS TO RESPONDENT HIGH STREET**

23 **(Failure to Maintain Compounding Training Documentation and Evaluation Process)**

24 160. Respondent High Street is subject to disciplinary action under Code section 4301(o)
25 in conjunction with California Code of Regulations, title 16, section 1735.7(a) and/or (b), in
26 conjunction with sections 4302 and/or 4156 of the Code, in that Respondent High Street directly
27 or indirectly violated, or attempted to violate, or assisted in or abetted a violation of, the statutes
28 or regulations regulating the practice of pharmacy. As discussed above in "Investigation 66051

1 Background," Respondent High Street failed to maintain written documentation, including
2 documentation of trainings, demonstrating that pharmacy personnel have the skills and training to
3 accurately perform their assigned responsibilities relating to compounding. Respondent High
4 Street further failed to develop and maintain an on-going competency evaluation process for
5 pharmacy personnel involved in compounding.

6 **FORTY-FIFTH CAUSE FOR DISCIPLINE**

7 **AS TO RESPONDENT AVAKIAN**

8 **(Failure to Maintain Compounding Quality Assurance Plan)**

9 161. Respondent Avakian is subject to disciplinary action under Code section 4301(o) in
10 conjunction with California Code of Regulations, title 16, section 1735.8, in that, either through
11 her own conduct or inaction, or derivatively as an owner of Respondent High Street or as a
12 Pharmacist-in-Charge under Code section 4113(c) and/or 4036.5, Respondent Avakian directly or
13 indirectly violated, or attempted to violate, or assisted in or abetted a violation of, the statutes or
14 regulations regulating the practice of pharmacy. As discussed above in "Investigation 66051
15 Background," Respondent Avakian failed to ensure that Respondent High Street maintained a
16 quality assurance plan designed to monitor and ensure the integrity, potency, quality, and labeled
17 strength of compounded drug products. Respondent Avakian further failed to ensure that any
18 such plan required all of the required standards and procedures.

19 **FORTY-SIXTH CAUSE FOR DISCIPLINE**

20 **AS TO RESPONDENT HIGH STREET**

21 **(Failure to Maintain Compounding Quality Assurance Plan)**

22 162. Respondent High Street is subject to disciplinary action under Code section 4301(o)
23 in conjunction with California Code of Regulations, title 16, section 1735.8, in conjunction with
24 sections 4302 and/or 4156 of the Code, in that Respondent High Street directly or indirectly
25 violated, or attempted to violate, or assisted in or abetted a violation of, the statutes or regulations
26 regulating the practice of pharmacy. As discussed above in "Investigation 66051 Background,"
27 Respondent High Street did not maintain a quality assurance plan designed to monitor and ensure
28

1 the integrity, potency, quality, and labeled strength of compounded drug products. Respondent
2 High Street further did not include in any such plan all of the required standards and procedures.

3 **FORTY-SEVENTH CAUSE FOR DISCIPLINE**

4 **AS TO RESPONDENT AVAKIAN**

5 **(Failure to Perform Complete Biennial Controlled Substance Inventory)**

6 163. Respondent Avakian is subject to disciplinary action under Code section 4301(o) and
7 Code of Federal Regulations, title 21, section 1304.11(a) and/or (c), in that, either through her
8 own conduct or inaction, or derivatively as an owner of Respondent High Street or as a
9 Pharmacist-in-Charge under Code section 4113(c) and/or 4036.5, Respondent Avakian directly or
10 indirectly violated, or attempted to violate, or assisted in or abetted a violation of, the statutes or
11 regulations regulating the practice of pharmacy. As discussed above in "Investigation 66051
12 Background," Respondent Avakian failed to ensure that Respondent High Street performed a
13 biennial controlled substance inventory containing a complete and accurate record of all
14 controlled substances on hand.

15 **FORTY-EIGHTH CAUSE FOR DISCIPLINE**

16 **AS TO RESPONDENT HIGH STREET**

17 **(Failure to Perform Complete Biennial Controlled Substance Inventory)**

18 164. Respondent High Street is subject to disciplinary action under Code section 4301(o)
19 and Code of Federal Regulations, title 21, section 1304.11(a) and/or (c), in conjunction with
20 sections 4302 and/or 4156 of the Code, in that Respondent High Street directly or indirectly
21 violated, or attempted to violate, or assisted in or abetted a violation of, the statutes or regulations
22 regulating the practice of pharmacy. As discussed above in "Investigation 66051 Background,"
23 Respondent High Street failed to perform a biennial controlled substance inventory containing a
24 complete and accurate record of all controlled substances on hand.

25 **OTHER MATTERS**

26 165. Pursuant to Code section 4307, if discipline is imposed on Pharmacy License No.
27 PHY 48720 issued to Respondent High Street, HS Pharmacy Inc. shall be prohibited from serving
28 as a manager, administrator, owner, member, officer, director, associate, or partner of a licensee

1 for five years if Pharmacy License No. PHY 48720 is placed on probation, or until Pharmacy
2 License No. PHY 48720 is reinstated if it is revoked.

3 166. Pursuant to Code section 4307, if discipline is imposed on Pharmacy License No.
4 PHY 48720 issued to Respondent High Street, and Gareen Avakian had knowledge of or
5 knowingly participated in any of the conduct for which Pharmacy License No. PHY 48720 was
6 disciplined, Gareen Avakian shall be prohibited from serving as a manager, administrator, owner,
7 member, officer, director, associate, or partner of a licensee for five years if Pharmacy License
8 No. PHY 48720 is placed on probation, or until Pharmacy License No. PHY 48720 is reinstated if
9 it is revoked.

10 **DISCIPLINE CONSIDERATIONS**

11 167. In order to determine the degree of discipline, if any, to be imposed, Complainant
12 alleges that on or around May 26, 2009, the Board issued Respondent High Street Citation No. CI
13 2008 38187. That citation is now final and is incorporated herein as if fully set forth.

14 **PRAYER**

15 WHEREFORE, Complainant requests that a hearing be held on the matters herein alleged,
16 and that following the hearing, the Board of Pharmacy issue a decision:

- 17 1. Revoking or suspending Pharmacist License No. RPH 44906, issued to Gareen
18 Avakian;
- 19 2. Revoking or suspending Pharmacy License No. PHY 48720, issued to HS Pharmacy
20 Inc. d.b.a. High Street Pharmacy, at Macarthur Blvd., Oakland, CA 94619;
- 21 3. Revoking or suspending Pharmacist License No. RPH 28204, issued to Kenneth Paul
22 Marinai;
- 23 4. Prohibiting HS Pharmacy Inc. from serving as a manager, administrator, owner,
24 member, officer, director, associate, or partner of a licensee for five years if Pharmacy License
25 PHY 48720 is placed on probation, or until Pharmacy License PHY 48720 is reinstated if
26 Pharmacy License PHY 48720 is revoked;
- 27 5. Prohibiting Gareen Avakian from serving as a manager, administrator, owner,
28 member, officer, director, associate, or partner of a licensee for five years if Pharmacy License


1 PHY 48720 is placed on probation, or until Pharmacy License PHY 48720 is reinstated if
2 Pharmacy License PHY 48720 is revoked;

3 6. Ordering Gareen Avakian and HS Pharmacy Inc. d.b.a. High Street Pharmacy, at
4 Macarthur Blvd., Oakland, CA 94619, to pay the Board of Pharmacy the reasonable costs of the
5 investigation and enforcement of this case, pursuant to Business and Professions Code section
6 125.3;

7 7. Ordering Kenneth Paul Marinai to pay the Board of Pharmacy the reasonable costs of
8 the investigation and enforcement of this case, pursuant to Business and Professions Code section
9 125.3;

10 8. Taking such other and further action as is deemed necessary and proper.

11
12 DATED: 4/13/17



VIRGINIA HEROLD
Executive Officer
Board of Pharmacy
Department of Consumer Affairs
State of California
Complainant

13
14
15 SF2015401182
16 41329850.doc
17
18
19
20
21
22
23
24
25
26
27
28